Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Felicia R. Cochran"'
Autor:
Michael A. Turner, Robert Spencer, Felicia R. Cochran, Mary Markert, Michael Saulino, Elizabeth Fehrmann, Katherine Stromberg, Keith Miesel
Publikováno v:
Neuromodulation: Technology at the Neural Interface. 20:187-197
OBJECTIVE The catheter status of patients who presented with loss of intrathecal baclofen (ITB) therapy effectiveness was investigated using measurements of cerebrospinal fluid (CSF) pressure transmitted through the catheter fluid path to the pump. T
Autor:
Jody L. Lutterman, Sean M. Mcgurran, Laxma G. Reddy, Kevin S. Gorski, Calin D. Dumitru, Elaine A. Egging, Kenneth E. Lipson, Melissa M. Piri, Gary W. Gullikson, Dave D. Johnson, Felicia R. Cochran, Mark A. Tomai, Mary A. Antonysamy, Joel Proksch
Publikováno v:
Cancer Immunology, Immunotherapy. 58:575-587
Innate immune stimulation with Toll-like receptor (TLR) agonists is a proposed modality for immunotherapy of melanoma. Here, a TLR7/8 agonist, 3M-011, was used effectively as a single systemic agent against disseminated mouse B16-F10 melanoma. The in
Autor:
Craig J. Schuller, David M. Hammerbeck, Elaine A. Egging, Gary R. Burleson, John P. Vasilakos, Woulfe Susan L, Felicia R. Cochran, Richard L. Miller, Mark A. Tomai
Publikováno v:
Antiviral Research. 73:1-11
Toll-like receptors (TLR) detect conserved molecular patterns expressed by pathogens. Detection of the "molecular signature" for RNA viruses including influenza has been attributed to TLR3, TLR7, and TLR8. In the present study, compound 3M-011 was sh
Publikováno v:
Medicinal Research Reviews. 16:547-563
Considerable evidence implicates NO as a mediator of inflammation and connective tissue injury in experimental models of arthritis as well as RA.
Autor:
Felicia R. Cochran
Publikováno v:
Expert Opinion on Investigational Drugs. 5:1399-1406
This article provides an up-to-date survey of conventional and investigational disease activity markers for rheumatoid arthritis. Measurements of clinically-assessed synovitis, radiographic damage, rheumatoid factor, acute phase reactants, and synovi
Autor:
Felicia R. Cochran, Michael P. Vitek
Publikováno v:
Expert Opinion on Investigational Drugs. 5:449-455
(1996). Monthly Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Neuroinflammatory mechanisms in Alzheimer's disease: new opportunities for drug discovery. Expert Opinion on Investigational Drugs: Vol. 5, No. 4, pp. 449-455.
Autor:
Felicia R. Cochran
Publikováno v:
Expert Opinion on Investigational Drugs. 4:875-878
Publikováno v:
ChemInform. 28
Considerable evidence implicates NO as a mediator of inflammation and connective tissue injury in experimental models of arthritis as well as RA.
Autor:
Ed W. McLean, Barrett R. Cooper, Jeffrey L. Selph, Ronda Davis, David Lee Musso, James L. Kelley, James B. Thompson, G Faye Orr, Greg C. Rigdon, Virgil L. Styles, Felicia R. Cochran, William R. Hall
Publikováno v:
Journal of medicinal chemistry. 46(3)
The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and beta-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally ac
Autor:
David Lee Musso, Jeffrey L. Selph, Greg C. Rigdon, Michael L. Jones, James L. Kelley, G Faye Orr, Felicia R. Cochran, Barrett R. Cooper
Publikováno v:
Journal of medicinal chemistry. 46(3)
Extension of the structure-activity relationship studies that led to the discovery of the nonsedating potent muscle relaxant, antiinflammatory, and analgesic agent (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 1, has given rise to (E)-2-(4-chloro-6-f